ORIGINAL RESEARCH article

Front. Immunol.

Sec. Systems Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1619434

This article is part of the Research TopicThe Uterus Immune Microenvironment Features in Physiological and Pathological ConditionsView all articles

Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors -a network metaanalysis

Provisionally accepted
Monika  GolinskaMonika Golinska1*Aleksander  RycerzAleksander Rycerz1Matylda  SobczakMatylda Sobczak1Jedrzej  ChrzanowskiJedrzej Chrzanowski1Konrad  StawiskiKonrad Stawiski1Wojciech  FendlerWojciech Fendler1,2
  • 1Department of Biostatistics and Translational Medicine, Medical University of Lodz, Łódź, Poland
  • 2Department of Radiation Oncology, Dana-Farber Cancer Institute,, Boston, MA, United States

The final, formatted version of the article will be published soon.

Background: Molecular events that drive endometriosis and cause accompanying immune deregulation remain elusive. Our purpose was to identify key molecular events involved in lesion formation across diverse populations and to detect transcriptomic changes in eutopic endometrium that accompany endometriosis.Methods: We searched Gene Expression Omnibus and ArrayExpress and performed differential gene expression analysis and a network meta-analysis on nine qualifying datasets. Those contained transcriptomic data on: 114 ectopic endometrium samples (EL), 138 eutopic endometrium samples from women with endometriosis (EEM) and 79 eutopic endometrium samples from women without endometriosis (EH). Gene ontology and enrichment analysis was performed in DAVID, Metascape and Cytoscape and drug repurposing was done in CMap.Results: EEM compared to EH upregulated CCL21 and downregulated BIRC3, CEL and LEFTY1 genes (|log2FC|>0.5, p<0.05). EL showed increased expression of complement and serpin genes (EL vs EEM: C7, logFC = 3.38, p <0.0001; C3, logFC = 2.40, p<0.0001; SERPINE1, logFC = 1.02; p<0.05; SERPINE2, logFC = 1.54, p<0.001) and mast cells markers (EL vs EEM: CPA3, logFC = 1.54, p<0.0001, KIT, logFC=0.74, p<0.001). Functional enrichment analysis highlighted complement and coagulation, inflammation, angiogenesis and extracellular matrix remodeling as drivers of endometriosis. Pharmacogenomic analysis indicated Janus Kinase (JAK), cyclin-dependent kinase (CDK) and topoisomerase inhibitors as therapy targets. Conclusion: Our results suggest an interplay between complement and coagulation, mast cells, extracellular matrix remodeling and JAK/STAT3 pathway in endometriosis. We underscore the significance of complement C3 and propose JAK inhibitors as therapy candidates. Detected expression differences between EEM and EH are important for the development of diagnosis via endometrial biopsy.

Keywords: Endometriosis, Eutopic and ectopic endometrium, Network meta-analysis, complement and coagulation, Mast Cells, Janus kinase (JAK) inhibitors

Received: 01 May 2025; Accepted: 11 Jun 2025.

Copyright: © 2025 Golinska, Rycerz, Sobczak, Chrzanowski, Stawiski and Fendler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Monika Golinska, Department of Biostatistics and Translational Medicine, Medical University of Lodz, Łódź, Poland

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.